Navigation Links
Vasogen Announces 2007 Year-End Results
Date:1/16/2008

without limitation, plans to advance the development of Celacade(TM) or VP025, plans to fund our current activities, statements concerning our partnering activities, health regulatory submissions, strategy, future operations, future financial position, future revenues and projected costs. In some cases, you can identify forward-looking statements by terminology such as "may", "will", "should", "expects", "plans", "anticipates", "believes", "estimated", "predicts", "potential", "continue", "intends", "could", or the negative of such terms or other comparable terminology. We made a number of assumptions in the preparation of these forward-looking statements, including assumptions about the nature, size, and accessibility of the market for Celacade in the treatment of chronic heart failure, particularly in Europe, the regulatory approval process leading to commercialization and the availability of capital on acceptable terms to pursue the development of Celacade, and the feasibility of additional trials. You should not place undue reliance on our forward-looking statements which are subject to a multitude of risks and uncertainties that could cause actual results, future circumstances or events to differ materially from those projected. These risks include, but are not limited to, the outcome of further ongoing analysis of the ACCLAIM trial results, the requirement or election to conduct additional clinical trials and the size and design of any such trials, delays or setbacks in the regulatory approval process, difficulties in the maintenance of existing regulatory approvals, securing and maintaining corporate alliances, the need for additional capital and the effect of capital market conditions and other factors on capital availability, the potential dilutive effects of any financing, risks associated with the outcomes of our preclinical and clinical research and development programs, the adequacy, timing, and results of our clinical trials, competition, market accept
'/>"/>
SOURCE Vasogen Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11

Related biology technology :

1. Vasogen Announces Third Quarter Conference Call and Webcast of Bio InvestorForum 2007 Presentation
2. Vasogen Announces Third Quarter 2007 Results
3. Vasogen to Webcast Presentations at Three Upcoming Healthcare Conferences
4. Vasogen Provides an Update on ACCLAIM-II Preparations
5. Vasogen and Grupo Ferrer Announce Initial Roll-out of Celacade - New Therapy for Chronic Heart Failure
6. Vasogen to Conduct Year-end 2007 Conference Call
7. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
8. YM BIOSCIENCES ANNOUNCES COMPLIANCE WITH AIM RULE 26
9. Emisphere Technologies, Inc. Announces Pricing of Registered Direct Offering
10. BioLife Solutions Announces Exclusive CryoStor(TM) Supply Agreement With the New England Cryogenic Center, Inc.
11. Carrington Announces Nasdaq Communication; Prepares for Shares to Be Quoted on the OTC Bulletin Board and Pink Sheets
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/27/2015)... 27, 2015 Junto Health, a company that ... and develop new technology solutions, today announced the launch ... a leader in health care policy consulting. Working together ... a collaborative innovation process while, at the same time, ... public policy, health care finance and the delivery of ...
(Date:7/24/2015)... , July 24, 2015 Ryan & Maniskas, ... in United States District Court for the Northern District of ... or entities that purchased the common stock of Avalanche Biotechnologies, ... July 31, 2014 and June 15, 2015, inclusive (the "Class ... 8, 2015, move the Court for appointment as a lead ...
(Date:7/24/2015)... Agritech Limited (NASDAQ GS: SEED) ("Origin", or the "Company"), a ... , today announced that the Company will report results for ... before the market opens on Wednesday, August 5th, 2015. ... 2015, at 9:00 a.m. ET / 9:00 p.m. ... in the call, please dial the following numbers approximately 5 ...
(Date:7/23/2015)... ... ... The health and wellness of brain tumor caregivers, often a spouse, parent, sibling ... American Brain Tumor Association presents interactive sessions that address shifting the mindset of caregivers ... Chicago. , “We have understood for a long-time now that caregivers and families ...
Breaking Biology Technology:Junto Health Announces a Unique Partnership with Sachs Policy Group 2Junto Health Announces a Unique Partnership with Sachs Policy Group 3Junto Health Announces a Unique Partnership with Sachs Policy Group 4Ryan & Maniskas, LLP Announces Class Action Lawsuit Against Avalanche Biotechnologies, Inc. 2Ryan & Maniskas, LLP Announces Class Action Lawsuit Against Avalanche Biotechnologies, Inc. 3Origin Agritech Limited to Announce Third Quarter Fiscal 2015 Unaudited Financial Results on August 5th, 2015 2Origin Agritech Limited to Announce Third Quarter Fiscal 2015 Unaudited Financial Results on August 5th, 2015 3Reframing the Caregiver and Patient Mindset: Coping with the ‘New Normal’ 2Reframing the Caregiver and Patient Mindset: Coping with the ‘New Normal’ 3
... -- LEUVEN, Belgium, September 30, 2010 ... ... ... are keyed by longUrl, so we need to grab the first one. for (var r in data.results) ...
... While refining their novel method for making nanoscale ... and Technology (NIST) discovered an unexpected bonusa new ... to that from light-emitting diodes (LEDs). These "nano-LEDs" ... to work serving miniature devices such as nanogenerators ...
... Sept. 29 /PRNewswire-FirstCall/ - Generex Biotechnology Corporation (Nasdaq: ... development, and commercialization of drug delivery systems and technologies, ... Mark Fletcher as Interim President and Chief Executive Officer ... an independent director, to serve as Chairman of the ...
Cached Biology Technology:ThromboGenics Signs Deal With MSD for Long-Term Commercial Supply of Microplasmin 2ThromboGenics Signs Deal With MSD for Long-Term Commercial Supply of Microplasmin 3ThromboGenics Signs Deal With MSD for Long-Term Commercial Supply of Microplasmin 4ThromboGenics Signs Deal With MSD for Long-Term Commercial Supply of Microplasmin 5ThromboGenics Signs Deal With MSD for Long-Term Commercial Supply of Microplasmin 6ThromboGenics Signs Deal With MSD for Long-Term Commercial Supply of Microplasmin 7ThromboGenics Signs Deal With MSD for Long-Term Commercial Supply of Microplasmin 8Growing nanowires horizontally yields new benefit: 'nano-LEDs' 2Generex Biotechnology Appoints Mark Fletcher as Interim President and CEO, and John P. Barratt as Chairman of the Board 2Generex Biotechnology Appoints Mark Fletcher as Interim President and CEO, and John P. Barratt as Chairman of the Board 3
(Date:7/2/2015)... DUBLIN , June 25, 2015 ... the addition of the "Next Generation Biometrics Market ... to 2020" report to their offering. ... $24.4 Billion by 2020, at a CAGR of 17.9% ... is the leading application for the market. Safran ...
(Date:6/26/2015)... SPRINGVILLE, Utah , June 26, 2015 ATL ... assemblies and devices with specialties in single use solutions, headquartered ... acquisition of MedConx, Inc. (a California ... , and San Jose, Costa Rica ). ... Costa Rica with ATL Technology,s existing ...
(Date:6/24/2015)... , June 24, 2015 This report provides ... the next six years. It contains an analysis of ... along with their impact from the short, medium, and ... discusses the industry, market, and technology trends that currently, ... need of concerned authorities to efficiently manage the increasing ...
Breaking Biology News(10 mins):Next Generation Biometrics Market 2015 - Global Forecast to 2020 with Safran, NEC, 3M Cogent, Fujitsu & Suprema Dominating the $24 Billion Market 2Next Generation Biometrics Market 2015 - Global Forecast to 2020 with Safran, NEC, 3M Cogent, Fujitsu & Suprema Dominating the $24 Billion Market 3ATL Technology Announces Acquisition of MedConx, Inc. and Expanded Global Footprint 2Automatic Identification System Market by Class, by Platform, by Application and by Geography - Global Forecasts & Analysis to 2014 - 2020 2
... In January 2012, the United States Department of Agriculture ... lunches more nutritious, which included requiring schools to increase ... fruit or vegetable with their purchased lunch. However, children ... a new study scheduled for publication in The ...
... the western Pacific Ocean may be losing their last ... to a paper published today in the scientific journal ... Researchers from the State University of Papua ... and World Wildlife Fund Indonesia released a report today ...
... The COMBACTE (Combatting Bacterial Resistance in Europe) project, resulting ... IMI, is one of the projects that is part ... It is the result of the initial association between ... run respectively by Marc Bonten of the University of ...
Cached Biology News:Libertarian paternalism and school lunches: Guiding healthier behavior while preserving choices 2New study shows continued decline in the last remaining stronghold for leatherback sea turtles 2COMBACTE: A new step in the fight against resistance to antibiotics 2COMBACTE: A new step in the fight against resistance to antibiotics 3
... stands both present the shaker ... and help protect user safety. ... steel, these heavy-duty accessories are ... and minimize the vibration produced ...
... (RNA polymers) are prepared ... of the enzyme, polynucleotide ... and the appropriate, ribonucleoside ... the exception of catalog ...
...
Anti-Tissue Trans-glutaminase (IgA) EIA Sample Size: 10 l...
Biology Products: